Ukuhlolwa Okusha Komtholampilo Kwe-Metastatic Castration-Resistant Prostate Cancer

Ibhalwe ngu umhleli

I-ESSA Pharma Inc., inkampani eyenza imithi esezingeni lomtholampilo egxile ekuthuthukiseni izindlela zokwelapha ezintsha zokwelapha umdlavuza wendlala yesinye, namuhla imemezele isiguli sokuqala esifakwe ocwaningweni oluxhaswe yiNkampani lweSigaba 1/2 ukuze kuhlolwe ukuphepha, ukubekezelelana nokusebenza kahle kwe-ESSA's. ikhandidethi lomkhiqizo ophambili, i-EPI-7386, i-N-terminal domain androgen receptor inhibitor yokuqala esigabeni sokuqala, ihlanganiswe ne-Astellas Pharma Inc.'s kanye ne-Pfizer Inc.'s ehlanganisa i-androgen receptor inhibitor, i- enzalutamide, ezigulini ezine- i-metastatic castration-resistant prostate cancer.

Phrinta Friendly, PDF & Imeyili

“Ukuqaliswa kwalolu cwaningo oluyinhlanganisela no-Astellas kuwumzuzu wamanzi we-ESSA njengoba siphenya inzuzo yomtholampilo engaba khona yokuvimbela i-androgen receptor ngokusebenzisa izindlela ezimbili ezizimele ekwelapheni iziguli ezine-mCRPC ezingakatholi ukwelashwa nge-antiandrogen yesizukulwane sesibili. izidakamizwa,” kusho uDkt. David. R. Parkinson, Isikhulu Esiphezulu, i-ESSA Pharma Inc. “Ukuhlanganisa izindlela zethu zokwelapha ezimbili kuzoqondisa ngesikhathi esisodwa iziphetho zombili zesamukeli se-androgen. Kumamodeli we-preclinical, sibonile ukuthi ukuhlanganisa i-EPI-7386 nama-antiandrogens amanje kungaholela ekuvinjweni okujulile nokubanzi kwe-androgen biology. Lesi sivivinyo seSigaba 1/2 siphawula okokuqala ochungechungeni lwezifundo zomtholampilo ukuhlola i-EPI-7386 kuhlanganiswe nemithi yamanje ye-antiandrogen ezigulini ezine-mCRPC, nokuhlolwa okwengeziwe kwenhlanganisela yeSigaba 1/2 okulindeleke ukuthi kuqale ngo-2022.

Uhlolo lomtholampilo lweSigaba 1/2 (NCT05075577) luqala ngengxenye yesigaba sokuqala lapho kulungiswa imithamo yomuthi ngamunye kulandelwa ingxenye yesigaba 1 lapho i-ejenti eyodwa enzalutamide iqhathaniswa nenhlanganisela ye- enzalutamide ne-EPI-2. Ucwaningo lwesigaba 7386 kulindeleke ukuthi lubhalise iziguli ezifika ku-1 ​​mCRPC ezingakaphathwa ngemithi yokwelapha ye-antiandrogen yesizukulwane sesibili. Umgomo wengxenye yesigaba 30 socwaningo ukuhlola ukuphepha nokubekezeleleka kwenhlanganisela yomuthi nokusungula imithamo enconyiwe yesigaba 1 ye-EPI-2 kanye ne enzalutamide lapho imithamo ihlanganiswa. Ucwaningo lwesigaba 7386 kulindeleke ukuthi lubhalise iziguli ze-2 mCRPC ezingakaphathwa ngemithi yokwelapha ye-antiandrogen yesizukulwane sesibili. Umgomo wesigaba sesi-120 sengxenye yocwaningo ukuhlola ukuphepha, ukubekezelelana nomsebenzi we-EPI-2 wokulwa nesimila kuhlanganiswe nomthamo ongashintshi we enzalutamide uma kuqhathaniswa ne- enzalutamide njenge-ejenti eyodwa.

Phrinta Friendly, PDF & Imeyili

Mayelana umbhali

umhleli

Umhleli omkhulu we-eTurboNew nguLinda Hohnholz. Uzinze e-eTN HQ e-Honolulu, e-Hawaii.

Shiya amazwana

eTurboNews | eTN